ArticleOphthalmic genetics
Ophthalmic artery chemosurgery for eyes with advanced retinoblastoma.
Article in Ophthalmic genetics. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 58 citations in OpenAlex.
- Topotecan Microneedle Scleral Patch: A Transscleral Drug Delivery Study for Retinoblastoma.Ophthalmology science · 2026Article
- In Vitro Stability and Preclinical Safety Evaluation of High-Dose Intravitreal Topotecan in Rabbits: Impact of Dose and Concentration.Ophthalmology science · 2026Article
- Ophthalmic Artery Chemosurgery for Retinoblastoma Babies Less than 3 Months Old or under 6-kg Weight.Ophthalmology. Retina · 2025Article
- Effect of intra-arterial chemotherapy drug regimens on globe salvage outcomes of retinoblastoma patients.The British journal of ophthalmology · 2025Article
- Advancements in Retinoblastoma Treatment: Unraveling the Potential of Intravitreal Chemotherapy.Cureus · 2024Review
- Pharmacokinetics of Orbital Topotecan After Ophthalmic Artery Chemosurgery and Intravenous Infusion in the Swine Model.Investigative ophthalmology & visual science · 2023Article
- Retinoblastoma gene expression profiling based on bioinformatics analysis.BMC medical genomics · 2023Article
- Outcome of salvage intra-arterial chemotherapy for recurrent retinoblastoma.Eye (London, England) · 2022Article
- Intra-Arterial Chemotherapy as Primary Treatment for Advanced Unilateral Retinoblastoma in China.Frontiers in medicine · 2022Article
- The Safety and Effectiveness of Melphalan-Based Intra-Arterial Chemotherapy for Retinoblastoma: An Updated Single-Arm Systematic Review and Meta-Analysis.Evidence-based complementary and alternative medicine : eCAM · 2022Article
- Treatment of Retinoblastoma: What Is the Latest and What Is the Future.Frontiers in oncology · 2022Review
- Review
- Intravenous Chemotherapy for Retinoblastoma in the Era of Intravitreal Chemotherapy: A Systematic Review.Ocular oncology and pathology · 2021Review
- Publication Trends of Research on Retinoblastoma During 2001-2021: A 20-Year Bibliometric Analysis.Frontiers in medicine · 2021Article
- Recent advancements in the management of retinoblastoma and uveal melanoma.Faculty reviews · 2021Review
- Modern treatment of retinoblastoma: A 2020 review.Indian journal of ophthalmology · 2020Review
- Retinoblastoma: Etiology, Modeling, and Treatment.Cancers · 2020Review
- Intra-arterial neuroprotective therapy as an adjunct to endovascular intervention in acute ischemic stroke: A review of the literature and future directions.Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences · 2020Review
- Survival and ocular preservation in a long-term cohort of Japanese patients with retinoblastoma.BMC pediatrics · 2020Article
- Combined intra-arterial chemotherapy and intravitreal melphalan for the treatment of advanced unilateral retinoblastoma.International journal of ophthalmology · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 2 countries.
Funding
Abstract
backgroundSurgical removal of one or both eyes has been the most common way to treat children with retinoblastoma worldwide for more than 100 years. Ophthalmic artery chemosurgery (OAC) was introduced 10 years ago and it has been used as an alternative to enucleation for eyes with advanced retinoblastoma. The purpose of this report is to analyze our 9-year experience treating advanced retinoblastoma eyes with OAC. MATERIALS AND
methodsSingle-arm retrospective study from a single center of 226 eyes with eyes of retinoblastoma patients with advanced intraocular disease defined as both Reese-Ellsworth (RE) "Va" or "Vb" and International Classification Retinoblastoma (ICRb) group "D" or "E" (COG Classification). Ocular survival, patient survival, second cancers, and electroretinography (ERG) were assessed.
resultsOcular survival at five years for these advanced eyes was 70.2% (95% confidence interval, 57.3%-79.8%). When eyes were divided into groups either by RE classification or ICRb, no significant differences in ocular survival were seen. Ocular survival was significantly better in naïve compared to non-naïve eyes (80.2% vs 58.4%, p = 0.041). The ERG distribution was very similar before and after OAC treatment for the patient population that did not receive intravitreal chemotherapy. Three patients (1.5%) have developed metastatic retinoblastoma (previously reported) and were successfully treated (no deaths).
conclusionUsing OAC for advanced eyes (the majority of such eyes have been enucleated in the past) enables 70% 5-year ocular survival. Treated eyes have a similar ERG distribution before and after treatment. No patient has died of metastatic retinoblastoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.